Abstract
One of the important purposes of apheresis in immune diseases is to remove EDA (+) fibronectin, which becomes elevated in the plasma of patients with serious rheumatoid arthritis, SLE, and rejection of kidney graft. We developed EDA (+) fibronectin adsorbent (OHC-10), but as described previously, it adsorbed not only EDA (+) fibronectin but also AT III and lipids. We recently developed a new adsorbent (OHC-20) which dose not adsorb AT III. Using 1 ml of OHC-20, a single pass test of 40ml blood was performed in 3 volunteers. Reduction rates were calculated for EDA (+) fibronectin, AT III, fibrinogen, cholesterol, triglyceride, and platelets. The reduction rate of EDA (+) fibronectin was more than 40%. One ml of OHC-20 could adsorb EDA (+) fibronectin in more than 40ml of blood. The reduction rate of AT III was less than 10%. Cholesterol and triglyceride were adsorbed to only a small degree. OHC-20 might be practical for the reduction of EDA (+) fibronectin.
